Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.
Ronan J KellyKeun-Wook LeeYung-Jue BangKhaldoun AlmhannaMariela Blum-MurphyDaniel V T CatenacciHyun Cheol ChungZev A WainbergMichael K GibsonJohanna C BendellCrystal S DenlingerCheng Ean CheeTakeshi OmoriRom LeidnerHeinz-Josef LenzYee ChaoMarlon C RebelattoPhilip Z BrohawnPeng HeJennifer McDevittSiddharth ShethJudson M EnglertGeoffrey Y KuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Response rates were low regardless of monotherapy or combination strategies. No new safety signals were identified. Including use of a tumor-based IFNγ signature and change in baseline and on-treatment circulating tumor DNA are clinically feasible and may be novel strategies to improve treatment response in this difficult-to-treat population.